Claims for Patent: 12,290,520
✉ Email this page to a colleague
Summary for Patent: 12,290,520
| Title: | Methods of use of emulsion formulations of aprepitant |
| Abstract: | Disclosed herein are novel pharmaceutical formulations of aprepitant suitable for parenteral administration including intravenous administration. Also included are formulations including both aprepitant and dexamethasone sodium phosphate. The pharmaceutical formulations are stable oil-in-water emulsions for non-oral treatment of emesis and are particularly useful for treatment of subjects undergoing highly emetogenic cancer chemotherapy. |
| Inventor(s): | Thomas B. Ottoboni, Han Han |
| Assignee: | Heron Therapeutics LLC |
| Application Number: | US18/408,463 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 12,290,520 |
| Patent Claims: |
1. An injectable emulsion, comprising: aprepitant; 13 wt/wt % to 20 wt/wt % of an egg lecithin; 9 wt/wt % to 10 wt/wt % of soybean oil; a co-emulsifier which is an alcohol, wherein the alcohol is present in the emulsion at less than 10 wt/wt %; a tonicity modifier; a pH modifier, wherein the pH modifier is sodium oleate; and water; wherein the ratio of egg lecithin to aprepitant is between about 20:1 to 25:1; wherein the pH of the emulsion ranges from about 7.5 to 9.0; and, wherein the emulsion is physically stable. 2. The emulsion of claim 1, wherein the egg lecithin is present in the emulsion at about 16 wt/wt %. 3. The emulsion of claim 1, wherein the egg lecithin is present in the emulsion at about 17 wt/wt %. 4. The emulsion of claim 1, wherein the ratio of egg lecithin to aprepitant is between about 24:1 to 25:1. 5. The emulsion of claim 1, wherein the ratio of egg lecithin to aprepitant is about 24:1. 6. The emulsion of claim 1, wherein the ratio of egg lecithin to aprepitant is about 25:1. 7. The emulsion of claim 1, wherein the alcohol in the emulsion is ethanol. 8. The emulsion of claim 7, wherein the ethanol is present in the emulsion at a concentration of about 2 wt/wt % to 3 wt/wt %. 9. The emulsion of claim 1, wherein the tonicity modifier in the emulsion is sucrose. 10. The emulsion of claim 9, wherein the sucrose is present at a concentration of about 3 wt/wt % to 8 wt/wt %. 11. The emulsion of claim 9, wherein the sucrose is present at a concentration of about 5 wt/wt %. 12. The emulsion of claim 1, wherein the pH modifier in the emulsion is sodium oleate. 13. The emulsion of claim 12, wherein the sodium oleate is present at a concentration of about 0.4 wt/wt % to 0.5 wt/wt %. 14. The emulsion of claim 1, wherein the aprepitant is present in the emulsion at about 0.7 wt/wt %. 15. The emulsion of claim 14, wherein the ratio of egg lecithin to aprepitant is between about 20:1 to 25:1. 16. The emulsion of claim 14, wherein the egg lecithin is present at a concentration of about 16 wt/wt %. 17. The emulsion of claim 14, wherein the egg lecithin is present at a concentration of about 17 wt/wt %. 18. The emulsion of claim 14, wherein the egg lecithin is present at a concentration of about 18 wt/wt %. 19. The emulsion of claim 14, wherein the ratio of egg lecithin to aprepitant is about 24:1. 20. The emulsion of claim 14, wherein the ratio of egg lecithin to aprepitant is about 25:1. 21. The emulsion of claim 1, comprising: about 16 wt/wt % to 17 wt/wt % of the egg lecithin; about 9 wt/wt % to 10 wt/wt % of the alcohol; about 3 wt/wt % to 8 wt/wt % of the tonicity modifier; and about 0.4 wt/wt % to 0.5 wt/wt % of the pH modifier. 22. The emulsion of claim 21, wherein the ratio of egg lecithin to aprepitant is between about 24:1 to 25:1. 23. The emulsion of claim 14, comprising: about 16 wt/wt % to 17 wt/wt % of the egg lecithin; about 9 wt/wt % to 10 wt/wt % of the alcohol; about 3 wt/wt % to 8 wt/wt % of the tonicity modifier; and about 0.4 wt/wt % to 0.5 wt/wt % of the pH modifier. 24. The emulsion of claim 23, wherein the ratio of egg lecithin to aprepitant is between about 24:1 to 25:1. |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
